Literature DB >> 22090088

[Recommendations for follow-up examinations in patients with ocular hypertension].

M Töteberg-Harms1, C Hirn, J Funk.   

Abstract

Ocular hypertension (OHT) describes a condition with elevated intraocular pressure (IOP) above the norm ( > 21 mmHg). By definition the anterior chamber angle is open and there are neither signs of glaucomatous optic nerve damage nor visual field defects. Thus, for the diagnosis of OHT an extensive baseline examination is mandatory in order to rule out pre-existing glaucomatous damage. Patients with ocular hypertension are at a higher risk of developing glaucoma. Therefore, periodical routine examinations with a standardized protocol for specific follow-up examinations are highly recommended.

Entities:  

Mesh:

Year:  2011        PMID: 22090088     DOI: 10.1007/s00347-011-2382-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  14 in total

1.  Distribution of intraocular pressure. The Barbados Eye Study.

Authors:  M C Leske; A M Connell; S Y Wu; L Hyman; A P Schachat
Journal:  Arch Ophthalmol       Date:  1997-08

Review 2.  Central corneal thickness, tonometry, and glaucoma risk--a guide for the perplexed.

Authors:  James D Brandt
Journal:  Can J Ophthalmol       Date:  2007-08       Impact factor: 1.882

3.  [Comparison of tonometry with the Keeler air puff non-contact tonometer "Pulsair" and the Goldmann applanation tonometer].

Authors:  A A Yücel; J Stürmer; B Gloor
Journal:  Klin Monbl Augenheilkd       Date:  1990-10       Impact factor: 0.700

4.  Estimation of width of angle of anterior chamber. Incidence and significance of the narrow angle.

Authors:  W Van Herick; R N Shaffer; A Schwartz
Journal:  Am J Ophthalmol       Date:  1969-10       Impact factor: 5.258

5.  A proposed simple method for measurement in the anterior chamber angle: biometric gonioscopy.

Authors:  N G Congdon; G L Spaeth; J Augsburger; J Klancnik; K Patel; D G Hunter
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

6.  The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975.

Authors:  H M Leibowitz; D E Krueger; L R Maunder; R C Milton; M M Kini; H A Kahn; R J Nickerson; J Pool; T L Colton; J P Ganley; J I Loewenstein; T R Dawber
Journal:  Surv Ophthalmol       Date:  1980 May-Jun       Impact factor: 6.048

7.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

8.  Central corneal thickness in the European Glaucoma Prevention Study.

Authors:  Norbert Pfeiffer; Valter Torri; Stefano Miglior; Thierry Zeyen; Ingrid Adamsons; Jose Cunha-Vaz
Journal:  Ophthalmology       Date:  2006-11-27       Impact factor: 12.079

Review 9.  Tonometry through the ages.

Authors:  Christoph Kniestedt; Omar Punjabi; Shan Lin; Robert L Stamper
Journal:  Surv Ophthalmol       Date:  2008 Nov-Dec       Impact factor: 6.048

Review 10.  Practical recommendations for measuring rates of visual field change in glaucoma.

Authors:  B C Chauhan; D F Garway-Heath; F J Goñi; L Rossetti; B Bengtsson; A C Viswanathan; A Heijl
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

View more
  2 in total

1.  [Fundus perimetry in functional diagnostics of glaucoma. Applicable in the practice?].

Authors:  K Rohrschneider; P C Issa; C Springer; A F Scheuerle
Journal:  Ophthalmologe       Date:  2012-04       Impact factor: 1.059

2.  [Are diurnal and nocturnal intraocular pressure measurements over 48 h justified?].

Authors:  N Fischer; F Weinand; M U Kügler; S Scheel; B Lorenz
Journal:  Ophthalmologe       Date:  2013-08       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.